HeartSciences Inc. (HSCS) Stock Analysis and Metrics

HeartSciences

NASDAQ: HSCS

$2.43 ▼ -0.01 (-0.59%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.29 Mn

P/E-0.33

P/S264.08

Div. Yield0.00

Total Debt (Qtr)3.12 Mn

Add ratio to table…

About

HeartSciences is a medical technology company focused on applying artificial intelligence to electrocardiogram ECG technology to enhance its clinical utility for detecting a broader range of heart conditions. The company develops AI ECG algorithms that are designed to identify cardiac dysfunction and other conditions that traditionally require imaging such as echocardiogram. These algorithms are integrated into its proprietary MyoVista wav ECG device which combines a standard 12 lead resting ECG with the AI ECG algorithm and also includes the Glasgow Algorithm for conventional ECG interpretation. In addition HeartSciences is building a cloud based platform the MyoVista Insights Cloud Platform that is intended to be hardware agnostic allowing existing ECG devices to upload data and receive AI ECG analysis from the company's internally developed algorithms or from third party contributors. The platform aims to provide efficient review reporting and storage of recorded ECGs while creating an marketplace for AI ECG algorithms. Neither the MyoVista wav ECG device the MyoVista Insights Cloud Platform nor any of the AI ECG algorithms have yet received clearance for marketing from the U S Food and Drug Administration. The company’s immediate goal is to obtain FDA clearance for its products and then launch them in clinical settings ranging from large health systems to frontline points of care such as primary care clinics.

HeartSciences intends to generate revenue primarily through the sale of its MyoVista wav ECG device under a razor and blade model where the device is sold together with proprietary electrodes that must be replaced after each test. In addition the company plans to earn recurring revenue from the use of its AI ECG algorithms either through usage fees or subscriptions via the MyoVista Insights Cloud Platform. The cloud platform is expected to charge fees for hosting the company's own AI ECG algorithms as well as for providing access to third party AI ECG algorithms that have obtained regulatory clearance. HeartSciences also anticipates that once its algorithms receive FDA clearance they will be eligible for reimbursement from third party payors including the Centers for Medicare and Medicaid Services and that the company will pursue appropriate CPT codes to facilitate billing. The initial commercial focus will be the United States and European markets where the company will employ a direct sales force in the United States and rely on medical device distributors with established healthcare relationships in Europe and other regions. The company believes that the combination of device sales consumable sales and algorithm based recurring revenue will create a diversified revenue stream as it expands its product offering.

The AI enhanced cardiac diagnostics market is emerging as a response to the limitations of conventional electrocardiography which has limited sensitivity in detecting structural and ischemic heart disease. According to the American Heart Association heart disease remains the leading cause of death in the United States with one person dying from cardiovascular disease every 34 seconds and annual costs exceeding 240 billion dollars. The global ECG market is projected to grow from approximately 10.93 billion dollars in 2023 to about 30.87 billion dollars in 2034 indicating strong demand for ECG related products. Despite this widespread use traditional ECGs often fail to detect early signs of disease such as impaired cardiac relaxation which is an early indicator of diastolic dysfunction and can precede symptoms by many years. HeartSciences seeks to close this diagnostic gap by adding AI ECG capability to the standard ECG test thereby enabling earlier detection of conditions such as low ejection fraction and diastolic dysfunction. Competitors in the space include established ECG manufacturers like GE Healthcare Philips and Nihon Kohden as well as newer artificial intelligence focused companies such as Anumana Tempus Labs and VIZ ai. The company’s competitive advantage stems from its proprietary AI ECG algorithms that aim to detect cardiac dysfunction without requiring new hardware and from its cloud based platform that allows existing ECG devices to access advanced analytics reducing the need for capital investment by healthcare providers.

The company serves a broad range of healthcare providers including hospitals health systems primary care clinics cardiology practices urgent care centers retail clinics and telemedicine settings. Early adopter pilots have already been established at two undisclosed medical institutions to test the MyoVista Insights Cloud Platform and integrate it into clinical workflows. HeartSciences intends to focus its sales efforts on health systems and large provider networks that can benefit from improved cardiac referral pathways and reduced reliance on costly imaging studies. In addition the company plans to target insurers and managed care organizations that have high enrollment in Medicare Advantage plans because there is a financial incentive to identify sicker patients earlier. The company also sees opportunities in specialty environments such as cardiology oncology drug trials and athlete screening programs where early detection of cardiac dysfunction can inform treatment decisions. Ultimately HeartSciences aims to provide its AI ECG solutions to any setting where a standard ECG is performed ranging from physician offices to emergency departments.

Investment Thesis

▲ Bull case

HeartSciences stands to gain transformative strategic value through its merger with Fortitude Mining Holdings, a vertically integrated Zcash mining platform wholly owned by Digital Currency Group (DCG), which provides immediate access to institutional-grade infrastructure, long-term power contracts, and disciplined capital allocation capabilities that HeartSciences previously lacked as a standalone medical technology firm. This combination resolves a critical historical constraint for HeartSciences: its dependence on dilutive equity financings to fund R&D and commercialization of its MyoVista Insights™ Platform and wavECG device. By becoming part of a cash-generative digital asset business with proven operational scale—Fortitude’s annualized ZEC production of 157,000 ZEC (approximately 366 ZEC per day) as of May 31, 2026—HeartSciences’ healthcare unit can now pursue product development and market expansion with greater financial stability and reduced capital-raising pressure, allowing management to focus on clinical validation, regulatory milestones, and hospital adoption cycles without the distraction of quarterly funding gaps. The merger effectively de-risks HeartSciences’ near-term execution by anchoring it to a parent with tangible cash flows from a high-growth, privacy-focused blockchain asset, creating a unique hybrid model where digital asset profitability funds healthcare innovation—a structure rarely seen in public markets and likely underestimated by investors focused solely on either sector in isolation.
The market is significantly underestimating the synergistic potential of combining HeartSciences’ AI-driven ECG technology with Fortitude’s venture mining ethos, particularly in how blockchain-based data integrity and privacy-preserving computation could enhance the security and scalability of MyoVista Insights™ in decentralized healthcare data ecosystems. As financial and health data increasingly converge on-chain, Zcash’s shielded transaction pool—designed for private, verifiable transactions—offers a technically superior foundation for handling sensitive ECG data compared to traditional cloud systems, potentially enabling HeartSciences to pioneer compliant, patient-controlled health data monetization or research data sharing models that align with emerging Web3 healthcare trends. Fortitude’s leadership, including CEO Andrea Childs and DCG founder Barry Silbert, has explicitly framed Zcash as a long-term bet on privacy-as-infrastructure in digital systems, a thesis that directly complements HeartSciences’ mission to improve clinical decision-making through secure, AI-enabled diagnostics; this ideological and technological alignment suggests the combined entity could develop novel use cases—such as zero-knowledge proofs for clinical trial data or encrypted remote patient monitoring—that neither company could pursue independently, creating a defensible innovation moat that transcends typical healthcare or crypto sector boundaries.
HeartSciences shareholders will retain meaningful economic exposure to both the legacy healthcare business and the high-upside digital asset platform through the all-stock structure of the transaction, with current HeartSciences CEO Andrew Simpson continuing to lead the healthcare unit post-close, ensuring operational continuity and strategic focus on MyoVista’s commercialization in cardiology markets—a critical factor often overlooked in merger analyses that assume acquirer dominance erodes target company vision. Unlike typical SPAC or cash deals that dilute or sideline legacy operations, this merger preserves HeartSciences’ identity as a distinct business unit while granting it access to Fortitude’s balance sheet strength and DCG’s network, effectively giving shareholders a call option on two asymmetric growth vectors: steady, if incremental, progress in AI-ECG adoption (supported by reduced cash burn) and explosive potential from Zcash’s continued appreciation, which has already delivered a trailing twelve-month return of approximately 1,000%+ as of June 15, 2026. The market appears to be pricing HSCS solely on its current healthcare fundamentals, ignoring the embedded optionality of owning a stake in a future-leading privacy-mining operation backed by one of the most influential players in digital assets, a mispricing that could correct sharply once the transaction closes and the combined entity begins reporting under the TUDE ticker with transparent segment-level performance.

HeartSciences stands to gain transformative strategic value through its merger with Fortitude Mining Holdings, a vertically integrated Zcash mining platform wholly owned by Digital Currency Group (DCG), which provides immediate access to institutional-grade infrastructure, long-term power contracts, and disciplined capital allocation capabilities that HeartSciences previously lacked as a standalone medical technology firm. This combination resolves a critical historical constraint for HeartSciences: its dependence on dilutive equity financings to fund R&D and commercialization of its MyoVista Insights™ Platform and wavECG device. By becoming part of a cash-generative digital asset business with proven operational scale—Fortitude’s annualized ZEC production of 157,000 ZEC (approximately 366 ZEC per day) as of May 31, 2026—HeartSciences’ healthcare unit can now pursue product development and market expansion with greater financial stability and reduced capital-raising pressure, allowing management to focus on clinical validation, regulatory milestones, and hospital adoption cycles without the distraction of quarterly funding gaps. The merger effectively de-risks HeartSciences’ near-term execution by anchoring it to a parent with tangible cash flows from a high-growth, privacy-focused blockchain asset, creating a unique hybrid model where digital asset profitability funds healthcare innovation—a structure rarely seen in public markets and likely underestimated by investors focused solely on either sector in isolation.
The market is significantly underestimating the synergistic potential of combining HeartSciences’ AI-driven ECG technology with Fortitude’s venture mining ethos, particularly in how blockchain-based data integrity and privacy-preserving computation could enhance the security and scalability of MyoVista Insights™ in decentralized healthcare data ecosystems. As financial and health data increasingly converge on-chain, Zcash’s shielded transaction pool—designed for private, verifiable transactions—offers a technically superior foundation for handling sensitive ECG data compared to traditional cloud systems, potentially enabling HeartSciences to pioneer compliant, patient-controlled health data monetization or research data sharing models that align with emerging Web3 healthcare trends. Fortitude’s leadership, including CEO Andrea Childs and DCG founder Barry Silbert, has explicitly framed Zcash as a long-term bet on privacy-as-infrastructure in digital systems, a thesis that directly complements HeartSciences’ mission to improve clinical decision-making through secure, AI-enabled diagnostics; this ideological and technological alignment suggests the combined entity could develop novel use cases—such as zero-knowledge proofs for clinical trial data or encrypted remote patient monitoring—that neither company could pursue independently, creating a defensible innovation moat that transcends typical healthcare or crypto sector boundaries.
HeartSciences shareholders will retain meaningful economic exposure to both the legacy healthcare business and the high-upside digital asset platform through the all-stock structure of the transaction, with current HeartSciences CEO Andrew Simpson continuing to lead the healthcare unit post-close, ensuring operational continuity and strategic focus on MyoVista’s commercialization in cardiology markets—a critical factor often overlooked in merger analyses that assume acquirer dominance erodes target company vision. Unlike typical SPAC or cash deals that dilute or sideline legacy operations, this merger preserves HeartSciences’ identity as a distinct business unit while granting it access to Fortitude’s balance sheet strength and DCG’s network, effectively giving shareholders a call option on two asymmetric growth vectors: steady, if incremental, progress in AI-ECG adoption (supported by reduced cash burn) and explosive potential from Zcash’s continued appreciation, which has already delivered a trailing twelve-month return of approximately 1,000%+ as of June 15, 2026. The market appears to be pricing HSCS solely on its current healthcare fundamentals, ignoring the embedded optionality of owning a stake in a future-leading privacy-mining operation backed by one of the most influential players in digital assets, a mispricing that could correct sharply once the transaction closes and the combined entity begins reporting under the TUDE ticker with transparent segment-level performance.

▼ Bear case

HeartSciences faces substantial execution risk in its healthcare business due to the merger’s structural shift toward Fortitude’s leadership and digital asset focus, which may result in diminished strategic priority and resource allocation for MyoVista Insights™ despite assurances that CEO Andrew Simpson will continue to lead the healthcare unit, as the combined company will operate under the Fortitude brand and be led by Fortitude’s management team headed by Andrea Childs, creating a clear hierarchy where healthcare innovation could be deprioritized in favor of scaling Zcash mining operations—a concern amplified by the absence of any disclosed financial commitments, budget guarantees, or dedicated capital reserves for HeartSciences’ R&D or commercialization efforts in the merger documentation, leaving its future dependent on the discretion of a parent whose core competency and investor base lie in volatile digital assets rather than medtech sales cycles.
The combined entity’s exposure to Zcash price volatility introduces material financial instability that could undermine HeartSciences’ healthcare operations, as Fortitude’s profitability—and thus its ability to fund non-core initiatives like medical technology R&D—is directly tied to the market price of ZEC, which has exhibited extreme swings historically and remains subject to regulatory crackdowns, shifts in miner profitability, or declining demand for privacy-focused transactions despite its trailing twelve-month return of approximately 1,000%+ as of June 15, 2026; a prolonged downturn in Zcash valuations could force Fortitude to curtail spending across all business units, including HeartSciences, precisely when the medtech unit may need sustained investment to achieve FDA clearances, expand clinical trials, or compete against entrenched ECG vendors, creating a dangerous dependency where healthcare innovation becomes hostage to cryptocurrency market sentiment rather than clinical or commercial milestones.
Investors are being asked to accept significant dilution and strategic uncertainty without clear visibility into the post-merger ownership structure, governance rights, or financial reporting transparency for HeartSciences’ legacy business, as the press release omits critical details such as the implied exchange ratio, projected ownership percentages for former HeartSciences shareholders in the combined company, or any commitment to standalone financial disclosure for the healthcare unit post-close, despite the cautionary note acknowledging risks related to “the integration of the two companies” and “the management of a newly public company”; this lack of specificity raises concerns that HeartSciences’ shareholders may end up with a minority stake in a entity where their original investment is subordinated to Fortitude’s DCG-backed agenda, and where the healthcare business could be gradually absorbed or underfunded without triggering material adverse change clauses, especially given that HeartSciences’ historical reliance on capital markets—evident from its need to seek a merger to escape constant fundraising—suggests it may lack the leverage to enforce protective terms in the final agreement, leaving its long-term viability as a standalone medtech innovator increasingly doubtful.

HeartSciences faces substantial execution risk in its healthcare business due to the merger’s structural shift toward Fortitude’s leadership and digital asset focus, which may result in diminished strategic priority and resource allocation for MyoVista Insights™ despite assurances that CEO Andrew Simpson will continue to lead the healthcare unit, as the combined company will operate under the Fortitude brand and be led by Fortitude’s management team headed by Andrea Childs, creating a clear hierarchy where healthcare innovation could be deprioritized in favor of scaling Zcash mining operations—a concern amplified by the absence of any disclosed financial commitments, budget guarantees, or dedicated capital reserves for HeartSciences’ R&D or commercialization efforts in the merger documentation, leaving its future dependent on the discretion of a parent whose core competency and investor base lie in volatile digital assets rather than medtech sales cycles.
The combined entity’s exposure to Zcash price volatility introduces material financial instability that could undermine HeartSciences’ healthcare operations, as Fortitude’s profitability—and thus its ability to fund non-core initiatives like medical technology R&D—is directly tied to the market price of ZEC, which has exhibited extreme swings historically and remains subject to regulatory crackdowns, shifts in miner profitability, or declining demand for privacy-focused transactions despite its trailing twelve-month return of approximately 1,000%+ as of June 15, 2026; a prolonged downturn in Zcash valuations could force Fortitude to curtail spending across all business units, including HeartSciences, precisely when the medtech unit may need sustained investment to achieve FDA clearances, expand clinical trials, or compete against entrenched ECG vendors, creating a dangerous dependency where healthcare innovation becomes hostage to cryptocurrency market sentiment rather than clinical or commercial milestones.
Investors are being asked to accept significant dilution and strategic uncertainty without clear visibility into the post-merger ownership structure, governance rights, or financial reporting transparency for HeartSciences’ legacy business, as the press release omits critical details such as the implied exchange ratio, projected ownership percentages for former HeartSciences shareholders in the combined company, or any commitment to standalone financial disclosure for the healthcare unit post-close, despite the cautionary note acknowledging risks related to “the integration of the two companies” and “the management of a newly public company”; this lack of specificity raises concerns that HeartSciences’ shareholders may end up with a minority stake in a entity where their original investment is subordinated to Fortitude’s DCG-backed agenda, and where the healthcare business could be gradually absorbed or underfunded without triggering material adverse change clauses, especially given that HeartSciences’ historical reliance on capital markets—evident from its need to seek a merger to escape constant fundraising—suggests it may lack the leverage to enforce protective terms in the final agreement, leaving its long-term viability as a standalone medtech innovator increasingly doubtful.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password